研究与报告

BaroPharm introduced BAROi Order, an AI tool that reads handwritten drug order sheets via photo, auto‑extracting product names and quantities to streamline pharmacy ordering.

Immunomic Therapeutics reported first patient dosing in a Phase 1 trial of ITI-9001, a Japanese cedar pollen allergy vaccine, with no safety issues observed.

Daewoong Pharmaceutical reports that its GERD treatment Peksuklu achieved symptom improvement in 95.75% of patients, including those 65+, in an interim post‑marketing surveillance study.

Mokam Life Science Institute and ST Pharm have signed a joint R&D agreement to develop AI‑based RNA design and optimization technology, aiming to boost next‑generation RNA therapeutic development.

Dong‑A Pharmaceutical introduced a smartphone barcode‑scan service that provides safety information for its over‑the-counter products, improving access for elderly and disabled consumers.

BeOne Medicines reports a Brukinsa regimen delivers a large progression‑free survival benefit, calling it a new chemotherapy‑free standard for first‑line mantle cell lymphoma.

CMI Media Group's new Ad Astra platform aims to bridge fragmented pharma marketing technologies, starting with omnichannel orchestration.

Novo Nordisk disclosed a limited internal IT breach and reported ransomware demands of $25 million from FulcrumSec and $50 million from TheUSERS007.

A Phase 3 combination trial of AbbVie and Genmab’s Epkinly showed positive results, restoring confidence after a recent second‑line monotherapy failure in diffuse large B‑cell lymphoma.

Pharmacists caution that taking ibuprofen or naproxen for delayed‑onset muscle soreness can interfere with the body’s natural healing process.

Consumer health leader Haleon has entered a five-year deal with Microsoft to embed AI across its business, reflecting a broader shift toward big‑tech digital overhauls in life sciences.

A Lancet study shows Chile's Food Labelling and Advertising Law lowers overweight and obesity risk among children by promoting healthier eating habits.